Hypokalemic periodic paralysis – what it is and how to spot it

Once in a lifetime: GP Dr James Chambers describes the unusual condition hypokalemic periodic paralysis (HypoPP) – a disorder mainly presenting in adolescents that GPs might rarely encounter

Note details of the case in this article have been altered to ensure anonymity

My attention was drawn to this condition by a recent case: a healthy, apparently well 14-year-old girl reported an unusual history that initially left me stumped. She told me that on waking that morning she hadn’t been able to get up off her top bunk bed; her legs simply wouldn’t move. She said she ‘lay there paralysed for a few hours’. I was surprised that she had presented to her GP rather than A&E, but she reassured me her father had calmly told her it was temporary and her strength would return – which it did. As she recounted the story, I found myself less concerned with the paralysis and more with why her father had expected it. He then explained that she was experiencing symptoms of hypokalemic periodic paralysis, a condition he has himself – along with several other family members – and that causes temporary episodes of paralysis. He asked that we inform his neurologist urgently for her to be assessed, which I did. I was also very curious to learn more about this condition I’d never encountered before.

What is it?

Hypokalemic periodic paralysis (hypoPP) is a rare, autosomal dominant disorder which is characterised by sudden, recurrent episodes of profound muscle weakness, triggered by low potassium levels.

The condition typically presents in adolescence, often with a profound and sudden onset of generalised weakness without an obvious trigger. On examination during an attack, patients usually demonstrate hyporeflexia and proximal muscle involvement with sparing of the ocular, bulbar or respiratory muscles.¹

Diagnosis can be challenging due to significant variability in the frequency and severity of episodes. Presentations can range from isolated, mild weakness to frequent episodes of complete paralysis. What makes it challenging is that between attacks, patients are asymptomatic and have normal examination findings and investigations.² This makes taking a detailed clinical history essential in identifying the condition.

Patients’ triggers can be subtle, and vary between patients. The commonest include rest after strenuous exercise and having a high carbohydrate meal. These factors promote an intracellular shift of potassium, mediated by insulin and noradrenaline,¹which precipitates an episode of paralysis. These underlying mechanisms are discussed in detail later in this article.

How rare is it?

HypoPP is a rare disorder, with an estimated prevalence of 1 per 100,000 people worldwide.³ This means it is unlikely on average that a GP will come across the condition, but cases may cluster in certain populations due to its familial inheritance.

Pathophysiology

The condition follows autosomal dominant inheritance, most commonly caused by mutations in the SCN4A and CACNAS1S genes. These genes encode voltage-gated sodium and calcium channels in skeletal muscle, which are essential for normal muscle excitability.

Essentially these mutations alter sodium ion channel function to create an abnormal influx of sodium ions into the cell. This influx causes a sustained depolarisation of the muscle membrane, rendering it inexcitable and unable to generate action potentials. This can be compensated for by the cell’s sodium-potassium ATPase pumps, which lower intracellular sodium levels by driving potassium into the cell. However, once a trigger causes potassium levels to fall, these compensatory mechanisms become insufficient, and muscle weakness is sustained.^1,4

Clues to early detection

HypoPP should be considered in patients presenting with recurrent episodes of flaccid weakness or paralysis, particularly when the following features are present (during an acute attack):

Rapid onset of weakness over minutes to hours, with a spontaneous recovery (time to recover varies from hours to days between patients).
Reduced muscle tone (flaccidity).
Bilateral, symmetrical weakness, predominantly affecting the proximal muscles.
Evidence of hypokalemia when the patient is symptomatic.
Onset typically in adolescence, with first presentation after the age of 20 uncommon.

Potential triggers should be carefully explored, including;

Rest after strenuous physical activity.
Intercurrent illness or fever.
Emotional or mental stress.
High carbohydrate meals, often precipitating symptoms on waking the next morning.
Prolonged immobility (e.g. long-haul flight).

A thorough family history is essential. Key findings could include:

A confirmed diagnosis of hypoPP in a first-degree relative.
Family members reporting similar episodic patterns of weakness or paralysis.

Not to be confused with…

HypoPP is part of a group of disorders known as muscle channelopathies, specifically a type of periodic paralysis (PP). HypoPP is the commonest type of these, but two examples of others include the inverse condition hyperkalemic periodic paralysis (hyperPP) and an even rarer condition called Anderson-Tawil syndrome.

Both hypoPP and hyperPP can present with similar episodic flaccid weakness. Differentiation is based on the serum potassium levels during attacks and their different underlying genetic mutations. Anderson-Tawil syndrome can be distinguished by its effect on heart muscle and characteristic dysmorphic features, alongside the episodic weakness.

Secondary causes of hypoPP should also be considered, such as in thyrotoxic periodic paralysis. Unlike primary hypoPP the condition is triggered by hyperthyroidism, where the high levels of thyroxine cause an increased intracellular shift of potassium resulting in hypokalemia and paralysis. This is more common in patients of Asian descent.

There are also many other causes of paralysis and weakness which need to be considered. These include Guillain-Barré syndrome, Myasthenia Gravis and Botulism. These conditions can often be distinguished by additional features such as sensory disturbance (e.g. peripheral neuropathy) or cranial nerve involvement including diplopia, dysphagia or dysarthria. They also do not typically present in adolescence.

Hypokalemia itself can also be a primary cause of weakness, so all hypokalemia identified during acute weakness cannot always be attributed towards hypoPP. Other causes include hyperaldosteronism, Liddell syndrome, chronic gastrointestinal losses, diuretic use, Bartter syndrome and Gitelman syndrome.⁵

Diagnosis, treatment and prognosis

The diagnosis and management of HypoPP depends on whether the patient presents during an acute paralytic episode or between episodes.

During an acute attack, a symptomatic patient should be reviewed urgently in a secondary care setting. This would be to confirm hypokalemia, exclude life-threatening cardiac involvement (with an ECG) and exclude rhabdomyolysis by measuring levels of creatinine kinase.

Outside of an acute episode, patients with suspected HypoPP should be referred urgently to a neurologist or geneticist, depending on local pathways. Thyroid function tests should be performed in primary care to exclude hyperthyroidism. Genetic testing is central to diagnosis, to identify those typical mutations seen within the condition. Where genetic testing is inconclusive but clinical suspicion remains high, provocation electromyography tests (EMG) are helpful, as these may demonstrate reduced muscle strength after intense physical activity. MRI scans of the proximal muscles, such as the thigh, can be helpful in patients with recurrent weakness to identify the extent of any myopathy.^1,5

Acute treatment during a paralytic episode is aimed at increasing serum potassium levels enough to trigger an intracellular shift of potassium, repolarising the skeletal muscle. In mild cases, this may be achieved with oral potassium replacement, ideally administered during the onset of symptoms or prodromal warning signs.^6,7 Patients with known HypoPP are often trained to self-administer this treatment under strict management plans. More severe attacks may require intravenous potassium replacement in a hospital setting, with cardiac and electrolyte monitoring in place.¹

Long-term management focuses on preventing attacks. Patients are advised to follow strict dietary advice including avoiding high carbohydrate and excessive sodium intake and increasing their potassium intake. Identifying and avoiding triggers in patients is critical in reducing the frequency and severity of attacks, so patients are often advised to avoid strenuous activity.¹

If lifestyle measures are insufficient, pharmacological therapy may be considered. Carbonic anhydrase inhibitors, such as acetazolamide, are commonly used. While their exact mechanism is not fully understood, they are thought to induce a mild metabolic acidosis that stabilises the membrane excitability and reduces intracellular shift.⁸Potassium sparing diuretics, such as spironolactone, also have a similar function and can work alongside carbonic anhydrase inhibitors to keep serum potassium levels stable.⁹ Patients often remain on these medications life-long to keep their potassium levels stabilised.

Key points for GPs

Hypokalemic periodic paralysis is a rare disorder which should be considered in an adolescent presenting with periodic episodes of weakness/paralysis, especially with a family history of the condition and/or similar symptoms.
Patients with suspected HypoPP should be sent immediately to secondary care during an acute crisis for prompt identification of hypokalemia and treatment.
Patients with suspected HypoPP should be urgently referred to a neurologist or geneticist (depending on local pathways) for further assessment.
Patients with known HypoPP will likely be aware of their triggers and have management plans including self-administration of potassium during the early stages of acute crisis. We should be aware of these management plans and facilitate them where appropriate.
Patients may be prescribed medications to manage the condition such as acetazolamide and spironolactone. It’s important we understand why these medications are prescribed and do not discontinue them suddenly.

Dr James Chambers is a GP in Staffordshire

References

Gadalla K, Anastasopoulou C. Hypokalemic Periodic Paralysis. [Updated 2025 Nov 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559178/
Periodic Paralysis Association. Hypokalemic Periodic Paralysis.
Venance S et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 2006;129:8–17
Berkely Lab. Structure reveals mechanism behind periodic paralysis. 2018
Weber F, Lehmann-Horn F. Hypokalemic Periodic Paralysis. 2002 Apr 30 [Updated 2018 Jul 26]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1338/
Lengelé J et al. Periodic paralyses: when channels go wrong. Nephrol Dial Transplant 2008;23(4):1098-101
Winczewska-Wiktor A et al. Myopathy as the first symptom of hypokalemic periodic paralysis – case report of a girl from a Polish family with CACNA1S (R1239G) mutation. Adv Med Sci 2007;52 (Suppl 1):155-7
Matthews E et al. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology 2011 Nov 29;77(22):1960-4
Abrishamkar S et al. Spironolactone in preventing hypokalemia following traumatic brain injury. Chin J Traumatol 2010;13(6):336-40